Challenges and Future Prospects of Targeting Myostatin/Activin A Signaling to Treat Diseases of Muscle Loss and Metabolic Dysfunction
The Journals of Gerontology: Series A · 16.06.2023 · 78 (Supplement_1) · 32-37
DOI: 10.1093/gerona/glad033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journals of Gerontology: Series A, online erschienen am 16.06.2023. Verfasst von Se-Jin Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA. Hauptthemen laut MEDLINE: Muscle, Skeletal, Myostatin. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIA NIH HHS, NIH HHS.
Abstract (Originalsprache)
Over the past 25 years, considerable progress has been made in terms of elucidating the regulatory and signaling mechanisms underlying the control of skeletal muscle mass by myostatin and other secreted proteins belonging to the transforming growth factor-β superfamily. Preclinical studies demonstrating the potential benefits of targeting the activities of these ligands have fueled the development of numerous biologics capable of perturbing this signaling pathway and increasing muscle mass and function. These biologics have been tested in numerous clinical trials for a wide range of indications characterized by muscle loss and excess adiposity. Here, we review the results of these trials and discuss some of the challenges and future prospects for targeting this signaling pathway to treat muscle and metabolic diseases. Myostatin inhibitors may improve metabolic outcomes by increasing muscle mass, and metabolic disorders may be attractive potential indications for these molecules.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.
- Department of Genetics and Genome Sciences, University of Connecticut School of Medicine, Farmington, Connecticut, USA.
- Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Versanis Bio, Inc., Oakland, California, USA.
- Eli Lilly, Inc., Indianapolis, Indiana, USA.
- Translational Medicine, Novartis Institute for BioMedical Research, Inc., Cambridge, Massachusetts, USA.
ORCID-Profile: Shalender Bhasin
Förderung
- NIAMS NIH HHS
- NIA NIH HHS
- NIH HHS
- NIDDK NIH HHS
- National Institutes of Health
- National Institute on Aging
Zitieren
APA
Lee, S. J., Bhasin, S., Klickstein, L., Krishnan, V., & Rooks, D. (2023). Challenges and Future Prospects of Targeting Myostatin/Activin A Signaling to Treat Diseases of Muscle Loss and Metabolic Dysfunction. The Journals of Gerontology: Series A, 78(Supplement_1), 32-37. https://doi.org/10.1093/gerona/glad033
Vancouver
Lee SJ, Bhasin S, Klickstein L, Krishnan V, Rooks D. Challenges and Future Prospects of Targeting Myostatin/Activin A Signaling to Treat Diseases of Muscle Loss and Metabolic Dysfunction. The Journals of Gerontology: Series A. 2023;78(Supplement_1):32-37. doi:10.1093/gerona/glad033
BibTeX
@article{Lee2023,
author = {Lee, Se-Jin and Bhasin, Shalender and Klickstein, Lloyd and Krishnan, Venkatesh and Rooks, Daniel},
title = {Challenges and Future Prospects of Targeting Myostatin/Activin A Signaling to Treat Diseases of Muscle Loss and Metabolic Dysfunction},
journal = {The Journals of Gerontology: Series A},
year = {2023},
volume = {78},
number = {Supplement_1},
pages = {32--37},
doi = {10.1093/gerona/glad033}
}
EUVIMED